High performance liquid chromatographyg-mass spectrometry assay for polymyxin B1 and B2 in human plasma

Therapeutic Drug Monitoring

Volumn 34, Issue 4, 2012, Pages 398-405

  Thomas, Tiffany A ^a   Broun, Emily C ^a   Abildskov, Kirsten M ^a   Kubin, Christine J ^b   Horan, Jennifer ^c   Yin, Michael T ^a   Cremers, Serge ^a  

^a NewYork Presbyterian Hospital   (United States)

^b Department of Orthopaedic Surgery   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

liquid chromatography mass spectrometry; multidrugresistant gram negative bacterial infections; pharmacokinetics; polymyxin B; therapeutic drug monitoring

Indexed keywords

COLISTIN; ION; POLYMYXIN; POLYMYXIN B; POLYMYXIN B1; POLYMYXIN B2; POLYMYXIN DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG;

ACCURACY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CALIBRATOR; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG HALF LIFE; DRUG MONITORING; DRUG PURIFICATION; DRUG STABILITY; ELECTROSPRAY MASS SPECTROMETRY; HEMOLYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERLIPIDEMIA; IONIZATION; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SOLID PHASE EXTRACTION;

ADULT; ANTI-BACTERIAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; DRUG STABILITY; FEMALE; HUMANS; MASS SPECTROMETRY; POLYMYXINS; SENSITIVITY AND SPECIFICITY;

EID: 84863825408     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31825c827a     Document Type: Article

References (28)

1. Orwa JA, Van Gerven A, Roets E, et al. Liquid chromatography of polymyxin B sulphate. J Chromatogr A. 2000;870:237-243. (Pubitemid 30077429)
2. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother. 1999;33:960-967. (Pubitemid 29420995)
3. Livermore DM. The need for new antibiotics. Clin Microbiol Infect. 2004;10(suppl 4):1-9.
4. Zavascki AP, Goldani LZ, Li J, et al. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother. 2007;60:1206-1215. (Pubitemid 350168315)
5. Tam VH, Schilling AN, Vo G, et al. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005;49:3624-3630. (Pubitemid 41233009)
6. Antoniadou A, Kontopidou F, Poulakou G, et al. Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. J Antimicrob Chemother. 2007;59:786-790. (Pubitemid 47073420)
7. Falagas ME, Bliziotis IA. Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era? Int J Antimicrob Agents. 2007;29:630-636. (Pubitemid 46710354)
8. Reis AO, Luz DA, Tognim MC, et al. Polymyxin-resistant Acinetobacter spp. isolates: what is next? Emerg Infect Dis. 2003;9:1025-1027. (Pubitemid 36944532)
9. Urban C, Mariano N, Rahal JJ, et al. Polymyxin B-resistant Acinetobacter baumannii clinical isolate susceptible to recombinant BPI and Cecropin P1. Antimicrob Agents Chemother. 2001;45:994-995. (Pubitemid 32182066)
10. David MD, Gill MJ. Potential for underdosing and emergence of resistance in Acinetobacter baumannii during treatment with colistin. J Antimicrob Chemother. 2008;61:962-964. (Pubitemid 351426087)
11. Cao G, Ali FE, Chiu F, et al. Development and validation of a reversed-phase high-performance liquid chromatography assay for polymyxin B in human plasma. J Antimicrob Chemother. 2008;62:1009-1014.
12. Cheng C, Liu S, Xiao D, et al. LC-MS/MS method development and validation of polymyxins and vancomycin in rat plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878:2831-2838.
13. Gobin P, Lemaitre F, Marchand S, et al. Assay of colistin and colistin methanesulfonate in plasma and urine by liquid chromatography-tandem mass spectrometry. Antimicrob Agents Chemother. 2010;54:1941-1948.
14. Haemers A, De Moerloose P: The identification of polymyxin B sulphate. J Chromatogr. 1970;52:154-157.
15. Howlett MR, Selzer GB. The identification of colistin and polymyxin B by thin-layer chromatography. J Chromatogr. 1967;30:630-631.
16. Jacobson M, Koch A, Kuntzman R, et al. The distribution and binding of tritiated polymyxin B in the mouse. J Pharmacol Exp Ther. 1972;183:433-439.
17. Kang JW, Van Schepdael A, Orwa JA, et al. Analysis of polymyxin B sulfate by capillary zone electrophoresis with cyclodextrin as additive. Method development and validation. J Chromatogr A. 2000;879:211-218. (Pubitemid 30303864)
18. Kotula Z, Piekut S, Kowszyk-Gindifer Z. Thin layer chromatography of polymyxin E and its methanesulfonate. Acta Pol Pharm. 1974;31:621-625.
19. Kwa AL, Lim TP, Low JG, et al. Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections. Diagn Microbiol Infect Dis. 2008;60:163-167.
20. Lemus Gallego JM, Perez Arroyo J. Micellar electrokinetic capillary chromatography as an alternative method for the determination of dexamethasone, trimethoprim, and polymyxin B. Fresenius J Anal Chem. 2001;370:973-975.
21. Srisom P, Liawruangrath B, Liawruangrath S, et al. Simultaneous determination of neomycin sulfate and polymyxin B sulfate by capillary electrophoresis with indirect UV detection. J Pharm Biomed Anal. 2007;43:1013-1018. (Pubitemid 46185816)
22. Stretton RJ, Carr JP, Watson-Walker J. The separation of neomycin sulphate, polymyxin B sulphate and zinc bacitracin. J Chromatogr. 1969;45:155-158.
23. He J, Ledesma KR, Lam WY, et al. Variability of polymyxin B major components in commercial formulations. Int J Antimicrob Agents. 2010;35:308-310.
24. Hermsen ED, Sullivan CJ, Rotschafer JC. Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications. Infect Dis Clin North Am. 2003;17:545-562.
25. Tam VH, Hou J, Kwa AL, et al. Comment on: Development and validation of a reversed-phase high-performance liquid chromatography assay for polymyxin B in human plasma. J Antimicrob Chemother. 2009;63:627-628; author reply 628-629.
26. Zavascki AP, Goldani LZ, Cao G, et al. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis. 2008;47:1298-1304.
27. Couet W, Gregoire N, Marchand S, et al. Colistin pharmacokinetics: the fog is lifting. Clin Microbiol Infect. 2012;18:30-39.
28. Li J, Turnidge J, Milne R, et al. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother. 2001;45:781-785. (Pubitemid 32182025)